- |||||||||| indapamide / Generic mfg.
Journal: A case of hyponatremia induced by the thiazide-like diuretic indapamide in an elderly woman (Pubmed Central) - Mar 31, 2025
However, in this case, hyponatremia was promptly detected shortly after the initiation of indapamide therapy, and no gastrointestinal symptoms other than anorexia were observed. When initiating thiazide-like diuretics, it is essential to be vigilant for hyponatremia and to provide appropriate medication guidance to patients in addition to monitoring their serum sodium levels.
- |||||||||| Observational data, Retrospective data, Journal: The Impact of Beta-Blockers and Renin-Angiotensin-Aldosterone System Inhibitors on the Prognosis of Atrial Fibrillation Patients with Chronic Obstructive Pulmonary Disease: A Nation-Wide Registry Study. (Pubmed Central) - Mar 18, 2025
Angiotensin converting enzyme inhibitors (ACEI) remained a protective factor for overall survival in AF patients with COPD (model 1: HR=0.45, 95% CI 0.21-0.98, P=0.045; model 2: HR=0.41, 95% CI 0.18-0.93, P=0.034; model 3: HR=0.38, 95% CI 0.16-0.89, P=0.026). Beta-blockers did not affect overall survival in patients with AF and COPD, whereas ACEI may be protective.
- |||||||||| Journal: Medicine Usage for Hypertension Management in Type 2 Diabetes Patients in the Rural-Urban Fringe Zone, Suzhou City, Jiangsu Province, China. (Pubmed Central) - Dec 16, 2024
In monotherapies, CCB had control rate of 41.2% (115/279, 95% CI 35.4%-47.2%), higher than combination (31.9%, 105/329, 95% CI 26.9%-37.3%), as well as ARB; the single reagent had control rate of 42.0% (95% CI 33.7%-50.7%), higher than combination (32.2%, 95% CI 27.4%-37.3%). More than 60% of T2DM patients had blood-pressures above the target level and the pattern of medications for HTN control in T2DM patients followed the recommendation of the authorities; however, the effects were not as expected, and more antihypertensive medicines or combinations would not raise the HTN control rate.
- |||||||||| Journal: Pharmacological Inhibition of P-Rex1/Rac1 Axis Blocked Angiotensin II-Induced Cardiac Fibrosis. (Pubmed Central) - Sep 28, 2024
Conclusion : Ang-II signaling plays an important role in the development of cardiac fibrosis and its downstream complications in SCD patients, which can be reversed by blockade of ATR1. Our findings demonstrated for the first time that P-Rex1 was an essential signaling mediator in CFs activation and subsequent cardiac fibrosis, and 1A-116 could be a potential pharmacological development drug.
- |||||||||| losartan / Generic mfg.
Correction of portal hypertension and renal dysfunction with losartan in patients with liver cirrhosis (virtual) - Mar 23, 2024 - Abstract #ERAEDTA2024ERA_EDTA_1010;
The present study indicates that angiotensin II blockade with orally administered losartan is safe and highly effective in the treatment of portal hypertension. In patients with liver cirrhosis with the development of impaired renal reabsorption function and a decrease in FPR from 10% to 8% in the treatment of portal hypertension, the drug of choice is an ARBs (losartan 25 mg/day) with blood pressure > 115/60 mmHg.
- |||||||||| Review, Journal: Engineering nanosystems for transdermal delivery of antihypertensive drugs. (Pubmed Central) - Feb 28, 2024
With benefits such as promoting patient compliance for long-time administration, enhancing skin permeability, and reducing systemic side effects, these systems are reasonably investigated and developed for the transdermal delivery of multiple antihypertensive drugs. This review aims to summarize the literature relating to nanosystem-based transdermal antihypertensive drug delivery and update recent advances in this field, as well as briefly discuss the challenges and prospects of engineering transdermal delivery nanosystems for hypertension treatment.
- |||||||||| losartan / Generic mfg.
A phase I/II trial on the use of losartan to treat children with recessive dystrophic epidermolysis bullosa (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3870;
Our trial data highlight that systemic losartan prevents disease progression, reduces inflammation, and improves the clinical picture. Although it is not a curative treatment for RDEB, it promises substantial benefits as a disease- modifying, systemic treatment, which has in combination the potential to enhance the efficacy of topical gene therapies.
- |||||||||| metformin / Generic mfg., telmisartan / Generic mfg.
Preclinical, Journal: Telmisartan versus metformin in downregulating myostatin gene expression and enhancing insulin sensitivity in the skeletal muscles of type 2 diabetic rat model. (Pubmed Central) - Aug 14, 2023
Histologically, telmisartan attenuated the morphological damage in the skeletal muscle fibers compared to diabetic rats, as evidenced by a considerable decrease in the collagen deposition area percentage and a reduction in NF-kB expression in the muscle tissues of group III. Telmisartan administration dramatically reduced myostatin and NF-kB expressions in skeletal muscles, which improved insulin resistance and glucose uptake in these muscles, highlighting a novel antidiabetic mechanism of telmisartan in treating T2DM.
- |||||||||| Journal: Antihypertensive Medications and PTSD Incidence in a Trauma Cohort. (Pubmed Central) - Aug 2, 2023
We found evidence that calcium channel blockers were associated with a decreased incidence of PTSD (adjusted hazard ratio =?0.63, 95% confidence interval [CI]?=?0.34, 1.2); all other antihypertensive medication classes had null or near null associations. These findings lay a foundation for additional research focusing on antihypertensive medications that appear most effective in reducing PTSD incidence following trauma and for additional replication work aimed at continuing to clarify the disparate findings reported in the literature to date.
- |||||||||| Review, Journal: Probiotics: functional food ingredients with the potential to reduce hypertension. (Pubmed Central) - Jul 23, 2023
Consequently, utilizing the probiotic function of probiotics in conjunction with the properties of functional foods to treat hypertension is a novel, side-effect-free treatment method. This study seeks to summarize the various factors that contribute to hypertension, the mechanism of probiotics in mitigating hypertension, and the fermented functional foods with probiotic strains, in order to provide a basis for the development of functional foods which utilize probiotics as their raw material and may have the potential to reduce hypertension.
- |||||||||| Review, Journal: Targeting G Protein-Coupled Receptors for Heart Failure Treatment. (Pubmed Central) - May 7, 2023
Many GPCR drug candidates are limited by insufficient efficacy and/or dose-limiting unwanted effects. Understanding the current challenges hindering successful clinical translation and the potential to overcome existing limitations will facilitate the future development of novel heart failure therapeutics.
- |||||||||| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Review, Journal: Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction. (Pubmed Central) - Jan 21, 2023
This manuscript reviews the current therapeutic algorithm with a special focus on the therapeutic value of adding an MRA (still underused in both clinical trials and real world), changing an ACEi/ARB for an ARNi and incorporating an SGLT2i in patients with HFrEF. This article is part of the Emerging concepts in heart failure management and treatment Special Issue: https://www.drugsincontext.com/special_issues/emerging-concepts-in-heart-failure-management-and-treatment.
- |||||||||| bleomycin / Generic mfg.
Journal: Major royal jelly proteins elicited suppression of SARS-CoV-2 entry and replication with halting lung injury. (Pubmed Central) - Jan 1, 2023
The efficiency of PF on SARS-CoV-2 replication (RNA-dependent RNA polymerase "RdRp" activity), as well as its impact on bleomycin-induced lung injury in vitro, were also assessed...Moreover, PF displayed protective and therapeutic efficacy against lung injury due to its antioxidant, anti-inflammatory, and angiotensin II blocking activities. The current findings, taken together, offer a novel perspective on PF as a promising agent against COVID-19.
- |||||||||| Journal: Antihypertensive Therapy and Incidence of Cancer. (Pubmed Central) - Nov 27, 2022
Finally, a positive association was found between angiotensin II receptor inhibitors and prostate cancer incidence (HR: 1.50, 95%CI: 1.28-1.65). These data suggest that diuretic use might be associated with liver cancer and lymphoid/haematopoetic tissue cancer development.
- |||||||||| Journal: Antihypertensive Use and the Risk of Cataract in Patients with Hypertension: A Nationwide Case-control Study. (Pubmed Central) - Nov 15, 2022
In a nationwide case-control study, the use of thiazide diuretics, beta-blockers, or ACE inhibitors do not represent minimal clinical important difference in the risk of cataract and the use of calcium channel blockers or angiotensin II receptor blockers is not associated with an increased risk of cataracts compared to non-use of each antihypertensive. Given the benefits of treating hypertension, such as the reduction in further complications, we suggest there is no need to change current clinical practice for antihypertensives.
- |||||||||| Journal: The role of the angiotensins in the pathogenesis of inflammatory joint disease (Pubmed Central) - Oct 29, 2022
The anti-inflammatory effect of drugs that block angiotensin II and its receptors, including in rheumatic diseases, can become practically significant for General therapists by their effect on reducing the concentration of inflammatory mediators and angiogenesis processes. The organoprotective and anti-inflammatory potentials of drugs that reduce the production of at demonstrated in vitro and in vivo experiments allow us to consider them as first-line angiotropic agents in patients with rheumatoid arthritis, especially in the presence of pathology of the cardiovascular system and kidneys.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
BLOCKADE OF ANGIOTENSIN-II AUGMENTS THE RESPONSIVENESS OF HUMAN LIVER CANCER CELLS TO LENVATINIB () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2019;
This combination regimen may provide advantageous outcomes to patients with intolerance to a common dose of lenvatinib due to adverse effects including hypertension. Given that AT-II blockers are clinically available without severe toxicities, they may eventually emerge as viable modulators of molecular targeted agents for patients with advanced HCC.
- |||||||||| Clinical, Review, Journal: Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension? (Pubmed Central) - Oct 23, 2022
We complete this presentation by outlining the current incipient but promising potential of immunotherapy to block angiotensin II pathology alone or possibly in combination with other antihypertensive drugs. A full appreciation of the magnitude of the residual risk associated with current renin angiotensin system-based therapies constitutes a vital underpinning for seeking new molecular approaches to halt or even reverse the cardiovascular complications of primary hypertension and encourage investigating a new generation of ACE inhibitors and ARBs with increased capacity to reach the intracellular compartments at which Ang II can be generated.
- |||||||||| losartan / Generic mfg.
Journal: Angiotensin II receptor type 1 blockade regulates Klotho expression to induce TSC2-deficient cell death. (Pubmed Central) - Oct 13, 2022
We show treatment of these cells with AGTR1 inhibitor losartan, or silencing of the Agtr1 gene leads to increased cell death in vitro and attenuates tumor progression in vivo...Therefore, we conclude that Agtr1 and Klotho are important for TSC2-deficient cell survival. These findings further illuminate the role of the renin-angiotensin system in LAM and the potential of targeting Agtr1 inhibition in TSC2-deficient cells.
- |||||||||| Journal: A rare case of alveolar hemorrhage with hypertensive emergency. (Pubmed Central) - Sep 20, 2022
This case indicates that severe hypertension can possibly cause alveolar hemorrhage. Accumulating these cases is important for general physicians to diagnose the alveolar hemorrhage with hypertensive emergency in its early stage and to avoid unnecessary treatment such as immunosuppressive therapy.
- |||||||||| valsartan / Generic mfg.
Journal: Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity. (Pubmed Central) - Sep 10, 2022
Our data show that 181-14 was not mutagenic in the transgenic gene mutation assay in MutaMice. The data support the conclusion that the Ames test is an adequate and sensitive test system to assess a mutagenic potential of nitrosamines.
- |||||||||| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Review, Journal: Application of Angiotensin Receptor-Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus. (Pubmed Central) - Aug 7, 2022
Recent studies have repeatedly confirmed that the first and so far the only angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan can reduce blood pressure more effectively than renin-angiotensin system inhibitors and improve the prognosis of heart failure in patients with CKD. Here, we propose clinical recommendations based on an expert consensus to guide ARNI-based therapeutics and reduce the occurrence of cardiovascular events in patients with CKD.
- |||||||||| Review, Journal: Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations. (Pubmed Central) - Jul 10, 2022
Pharmacological trials involving beta-blockers, angiotensin II receptor antagonists, aldosterone antagonists, and angiotensin-neprilysin inhibitors have demonstrated encouraging results, but have yet to reach the significance of advancements made in the treatment of heart failure with reduced ejection fraction. This review aims to summarize landmark clinical trials that have influenced current treatment guidelines, and reports on emerging evidence supporting/refuting new treatment modalities including pharmacotherapy, lifestyle modification and device therapy.
- |||||||||| losartan potassium / Generic mfg.
Journal: Pharmacological blockade of angiotensin II receptor restores diabetes-associated reduction of store operated Ca entry in adult cardiomyocytes. (Pubmed Central) - May 18, 2022
We also included another group of rats with diabetes induced by STZ administration but received an angiotensin II receptor blocker - losartan...The observed imbalance between the functional read out of SOCE (peak I size) and expression levels of the underlying proteins was puzzling but could be, among other possibilities, due to impairment of interaction between Stim and Orai proteins. We argue that the observed changes in SOCE with diabetes could be a contributing factor for the Ca dyshomeostasis associated with diabetic cardiomyopathies and blockade of angiotensin II receptor may potentially restore normal SOCE in diabetic cardiomyocytes.
- |||||||||| propranolol / Generic mfg.
Preclinical, Journal: Sexual dimorphism in AngII/AT R-mediated cognitive and cardiovascular dysfunction in a mouse model of Alzheimer's Disease. (Pubmed Central) - May 14, 2022
BPV was calculated as SD of BP, while resting cardiac sympathetic tone was estimated as the HR response to b-adrenergic receptor antagonist propranolol (2 mg/kg, IP)...Surprisingly, AT R expression in the LV of E4 female mice was 10-times higher versus other tissues, despite normal cardiac function (mouse echocardiography). Collectively, the data from this study suggests that enhanced AngⅡ/AT R signaling in the female ApoE4 carriers, contributes to cardiovascular and cognitive decline with aging.
|
